

Steve Sisolak  
Governor



Richard Whitley, MS  
Director

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

*Helping people. It's who we are and what we do.*



Suzanne Bierman,  
JD MPH  
Administrator

December 6, 2022

Inter-Tribal Council of Nevada  
Serrell Smokey, ITCN President  
Tribal Chairman of Washoe Tribe  
919 Highway 395 S  
Gardnerville, Nevada 89410

Dear Tribal Members:

In accordance with established consultation guidelines, the Division of Health Care Financing and Policy (DHCFP) is notifying Nevada tribes of the following proposed change in policy:

The DHCFP is proposing revisions to Medicaid Services Manual (MSM) Chapter 1200 – Prescribed Drugs to reflect recommendations approved on October 20, 2022, by the Drug Utilization Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Vivjoa<sup>®</sup> (oteseconazole) within the Anti-Fungal Agents section; addition of new prior authorization criteria for Voquenza<sup>®</sup> Dual Pak<sup>®</sup> (Vonoprazan and amoxicillin), and Voquenza<sup>®</sup> Triple Pak<sup>®</sup> (Vonoprazan, amoxicillin, and clarithromycin) within the new Qualified Infection Disease Product Section; addition of new prior authorization criteria for Livtency<sup>®</sup> (maribravir) in the Antivirals section; addition of new prior authorization criteria for Cuvrior<sup>®</sup> (trientine tetrahydrochloride) within the new Copper Chelator section; addition of new prior authorization criteria for Pyrukynd<sup>®</sup> (mitapivat) within the new Pyruvate Kinase Activators section; revisions to the existing Provigil<sup>®</sup> (modafinil) and Nuvigil<sup>®</sup> (armodafinil) to include clinical criteria for the treatment of Obstructive Sleep Apnea (OSA) within the Narcolepsy Agents section; addition of new prior authorization criteria for Kynmobi<sup>®</sup> (apomorphine) in the new Anti-Parkinson's Agents section; addition of new prior authorization criteria for Amvuttra<sup>®</sup> (Vutrisiran) within the new Amyloidosis-Agents Transthyretin (TTR) Suppression (P9B) section; revisions to the existing immunomodulator drugs criteria; revision to the existing Topical Androgens and Gender Edits, which include the addition of new prior authorization criteria for Oral testosterone products within the Hormones and Hormones Modifiers section; and addition of new prior authorization criteria for Oxervate<sup>®</sup>(cenegermin-bkbj) within the new Ophthalmic Human Nerve Growth Factor (Q25) Section.

There is no anticipated fiscal impact to the Tribal Governments.

If you would like a consultation regarding this proposed change in policy, please contact Monica Schiffer at (775) 684-3653 who will schedule a meeting. We would appreciate a reply within 30 days from the date of this letter. If we do not hear from you within this time, we will consider this an indication that no consultation is requested.

Sincerely,

Casey Angres

Casey Angres (Dec 6, 2022 16:14 PST)

Casey Angres  
Manager of Division Compliance, DHCFP

cc: Antonina Capurro, DMD, Deputy Administrator, DHCFP  
Sandie Ruybalid, CPM, Deputy Administrator, DHCFP  
Antonio Gudino-Vargas, SSPS III, Pharmacy Services, DHCFP  
Kindra Berntson, SSPS II, Pharmacy Services, DHCFP  
Monica Schiffer, SSPS III, Medical Programs Unit, DHCFP